A multicenter, double-blind, randomized, parallel groups placebo-controlled study to assess the efficacy and safety of fexofenadine 120mg BID in subjects with mild to moderate persistent asthma.
Phase of Trial: Phase III
Latest Information Update: 07 Jul 2009
At a glance
- Drugs Fexofenadine (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Aventis Pharmaceuticals
- 20 Aug 2008 Primary and secondary endpoints added as reported by ClinicalTrials.gov.
- 20 Aug 2008 Actual initiation date changed from Jan 2002 to Feb 2002 as reported by ClinicalTrials.gov.
- 20 Aug 2008 Actual end date (Oct 2003) added as reported by ClinicalTrials.gov.